Cargando…

Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients

BACKGROUND: Lung cancer is one of the most common malignant neoplasms worldwide and has a high mortality rate. To enable individualized therapy regimens, a better understanding of the molecular tumor biology has still to be elucidated. The expression of the cell surface protein CD24 has already been...

Descripción completa

Detalles Bibliográficos
Autores principales: Majores, Michael, Schindler, Anne, Fuchs, Angela, Stein, Johannes, Heukamp, Lukas, Altevogt, Peter, Kristiansen, Glen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647809/
https://www.ncbi.nlm.nih.gov/pubmed/26578846
http://dx.doi.org/10.1186/s12907-015-0019-z
_version_ 1782401163442782208
author Majores, Michael
Schindler, Anne
Fuchs, Angela
Stein, Johannes
Heukamp, Lukas
Altevogt, Peter
Kristiansen, Glen
author_facet Majores, Michael
Schindler, Anne
Fuchs, Angela
Stein, Johannes
Heukamp, Lukas
Altevogt, Peter
Kristiansen, Glen
author_sort Majores, Michael
collection PubMed
description BACKGROUND: Lung cancer is one of the most common malignant neoplasms worldwide and has a high mortality rate. To enable individualized therapy regimens, a better understanding of the molecular tumor biology has still to be elucidated. The expression of the cell surface protein CD24 has already been claimed to be associated with shorter patient survival in non-small cell lung cancer (NSCLC), however, the prognostic value and applicability of CD24 immunostaining in paraffin embedded tissue specimens has been questioned due to the recent acknowledgement of restricted epitope specificity of the commonly used antibody SN3b. METHODS: A cohort of 137 primary NSCLC cases was immunostained with a novel CD24 antibody (clone SWA11), which specifically recognizes the CD24 protein core and the resulting expression data were compared with expression profiles based on the monoclonal antibody SN3b. Furthermore, expression data were correlated to clinico-pathological parameters. Univariate and multivariate survival analyses were conducted with Kaplan Meier estimates and Cox regression, respectively. RESULTS: CD24 positivity was found in 34 % resp. 21 % (SN3b) of NSCLC with a membranous and/or cytoplasmic staining pattern. Kaplan-Meier analyses revealed that membranous, but not cytoplasmic CD24 expression (clone SWA11) was associated with lympho-nodular spread and shorter overall survival times (both p < 0.05). CD24 expression established by SN3b antibodies did not reveal significant clinicopathological correlations with overall survival, neither for cytoplasmic nor membranous CD24 staining. CONCLUSIONS: Membranous CD24 immunoreactivity, as detected with antibody clone SWA11 may serve as a prognostic factor for lymphonodular spread and poorer overall survival. Furthermore, these results corroborate the importance of a careful distinction between membranous and cytoplasmic localisation, if CD24 is to be considered as a potential prognostic biomarker.
format Online
Article
Text
id pubmed-4647809
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46478092015-11-18 Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients Majores, Michael Schindler, Anne Fuchs, Angela Stein, Johannes Heukamp, Lukas Altevogt, Peter Kristiansen, Glen BMC Clin Pathol Research Article BACKGROUND: Lung cancer is one of the most common malignant neoplasms worldwide and has a high mortality rate. To enable individualized therapy regimens, a better understanding of the molecular tumor biology has still to be elucidated. The expression of the cell surface protein CD24 has already been claimed to be associated with shorter patient survival in non-small cell lung cancer (NSCLC), however, the prognostic value and applicability of CD24 immunostaining in paraffin embedded tissue specimens has been questioned due to the recent acknowledgement of restricted epitope specificity of the commonly used antibody SN3b. METHODS: A cohort of 137 primary NSCLC cases was immunostained with a novel CD24 antibody (clone SWA11), which specifically recognizes the CD24 protein core and the resulting expression data were compared with expression profiles based on the monoclonal antibody SN3b. Furthermore, expression data were correlated to clinico-pathological parameters. Univariate and multivariate survival analyses were conducted with Kaplan Meier estimates and Cox regression, respectively. RESULTS: CD24 positivity was found in 34 % resp. 21 % (SN3b) of NSCLC with a membranous and/or cytoplasmic staining pattern. Kaplan-Meier analyses revealed that membranous, but not cytoplasmic CD24 expression (clone SWA11) was associated with lympho-nodular spread and shorter overall survival times (both p < 0.05). CD24 expression established by SN3b antibodies did not reveal significant clinicopathological correlations with overall survival, neither for cytoplasmic nor membranous CD24 staining. CONCLUSIONS: Membranous CD24 immunoreactivity, as detected with antibody clone SWA11 may serve as a prognostic factor for lymphonodular spread and poorer overall survival. Furthermore, these results corroborate the importance of a careful distinction between membranous and cytoplasmic localisation, if CD24 is to be considered as a potential prognostic biomarker. BioMed Central 2015-11-16 /pmc/articles/PMC4647809/ /pubmed/26578846 http://dx.doi.org/10.1186/s12907-015-0019-z Text en © Majores et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Majores, Michael
Schindler, Anne
Fuchs, Angela
Stein, Johannes
Heukamp, Lukas
Altevogt, Peter
Kristiansen, Glen
Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients
title Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients
title_full Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients
title_fullStr Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients
title_full_unstemmed Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients
title_short Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients
title_sort membranous cd24 expression as detected by the monoclonal antibody swa11 is a prognostic marker in non-small cell lung cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647809/
https://www.ncbi.nlm.nih.gov/pubmed/26578846
http://dx.doi.org/10.1186/s12907-015-0019-z
work_keys_str_mv AT majoresmichael membranouscd24expressionasdetectedbythemonoclonalantibodyswa11isaprognosticmarkerinnonsmallcelllungcancerpatients
AT schindleranne membranouscd24expressionasdetectedbythemonoclonalantibodyswa11isaprognosticmarkerinnonsmallcelllungcancerpatients
AT fuchsangela membranouscd24expressionasdetectedbythemonoclonalantibodyswa11isaprognosticmarkerinnonsmallcelllungcancerpatients
AT steinjohannes membranouscd24expressionasdetectedbythemonoclonalantibodyswa11isaprognosticmarkerinnonsmallcelllungcancerpatients
AT heukamplukas membranouscd24expressionasdetectedbythemonoclonalantibodyswa11isaprognosticmarkerinnonsmallcelllungcancerpatients
AT altevogtpeter membranouscd24expressionasdetectedbythemonoclonalantibodyswa11isaprognosticmarkerinnonsmallcelllungcancerpatients
AT kristiansenglen membranouscd24expressionasdetectedbythemonoclonalantibodyswa11isaprognosticmarkerinnonsmallcelllungcancerpatients